Rankings
▼
Calendar
ALKS Q1 2023 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$288M
+3.2% YoY
Gross Profit
$229M
79.8% margin
Operating Income
-$11M
-3.8% margin
Net Income
-$42M
-14.5% margin
EPS (Diluted)
$-0.25
QoQ Revenue Growth
-5.6%
Cash Flow
Operating Cash Flow
-$21M
Free Cash Flow
-$28M
Stock-Based Comp.
$21M
Balance Sheet
Total Assets
$1.9B
Total Liabilities
$917M
Stockholders' Equity
$1.0B
Cash & Equivalents
$321M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$288M
$279M
+3.2%
Gross Profit
$229M
$223M
+2.7%
Operating Income
-$11M
-$27M
+58.7%
Net Income
-$42M
-$36M
-16.6%
Revenue Segments
Product
$215M
50%
Vivitrol
$97M
23%
Aristada And Aristada Initio
$80M
19%
L Y B A L V I
$38M
9%
← FY 2023
All Quarters
Q2 2023 →